MODUS THERAPEUTICS HOLDING AB Financials Modus Therapeutics Holding AB
Equities
MODTX
SE0015987904
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.05 SEK | -8.30% |
|
+4.48% | -39.48% |
Valuation
| Fiscal Period: December | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 61.18 | 62.35 | 37.74 | - | - |
| Enterprise Value (EV) 1 | 61.18 | 62.35 | 24.74 | -9.264 | 36.74 |
| P/E ratio | - | -1.72 x | -1.4 x | -1.01 x | -0.83 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -2.96 x | - | -0.99 x | 0.26 x | -0.83 x |
| EV / FCF | - | - | -0.92 x | 0.25 x | -0.82 x |
| FCF Yield | - | - | -109% | 399% | -122% |
| Price to Book | - | - | 3.18 x | 0.83 x | - |
| Nbr of stocks (in thousands) | 16,100 | 35,939 | 35,939 | - | - |
| Reference price 2 | 3.800 | 1.735 | 1.050 | 1.050 | 1.050 |
| Announcement Date | 22-02-22 | 24-02-21 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales | 0.002 | - | - | - | - | - |
| EBITDA 1 | - | -20.69 | - | -25 | -36 | -44 |
| EBIT 1 | - | -20.69 | - | -25 | -36 | -44 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | -27 | -37 | -45 |
| Net income 1 | -6.019 | - | -17.9 | -27 | -37 | -45 |
| Net margin | -300,950% | - | - | - | - | - |
| EPS 2 | - | - | -1.010 | -0.7500 | -1.040 | -1.260 |
| Free Cash Flow 1 | - | - | - | -27 | -37 | -45 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 21-04-14 | 22-02-22 | 24-02-21 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 13 | 47 | 1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -27 | -37 | -45 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 0.3300 | 1.270 | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 21-04-14 | 22-02-22 | 24-02-21 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.48% | 3.48M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- MODTX Stock
- Financials Modus Therapeutics Holding AB